Cargando…
Erectile dysfunction as a marker of endocrine and glycemic disorders
PURPOSE: The aim of this study was to evaluate in a population of patients with erectile dysfunction (ED): (a) the prevalence of a previously unknown endocrine/glycemic disorders; (b) the correlation between ED severity and endocrine/glycemic disorders. METHODS: 1332 patients referred for ED from 20...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270283/ https://www.ncbi.nlm.nih.gov/pubmed/35366160 http://dx.doi.org/10.1007/s40618-022-01788-5 |
_version_ | 1784744428325306368 |
---|---|
author | Mazzilli, R. Zamponi, V. Olana, S. Mikovic, N. Cimadomo, D. Defeudis, G. Faggiano, A. |
author_facet | Mazzilli, R. Zamponi, V. Olana, S. Mikovic, N. Cimadomo, D. Defeudis, G. Faggiano, A. |
author_sort | Mazzilli, R. |
collection | PubMed |
description | PURPOSE: The aim of this study was to evaluate in a population of patients with erectile dysfunction (ED): (a) the prevalence of a previously unknown endocrine/glycemic disorders; (b) the correlation between ED severity and endocrine/glycemic disorders. METHODS: 1332 patients referred for ED from 2013 to 2020 were included. The ED diagnosis was made using the International-Erectile-Function-Index-5 questionnaire. ED severity was considered according to presence/absence of spontaneous erections, maintenance/achievement deficiency. All patients were subjected to search for sociodemographic and clinical characteristics: age, ethnicity, marital status, previous use of PDE5i, previous prostatectomy, diabetes mellitus (DM), prediabetes, endocrine dysfunctions. RESULTS: The mean ± SD age was 54.3 ± 13.7 years. The 19.1% (255/1332) of patients were already in treatment for prediabetes/diabetes or endocrine dysfunctions. Among the remaining 1077, the prevalence of previously unknown endocrine and glycemic disorders was 30% (323/1077). Among them, 190/323 subjects (58.8%) were affected by hypogonadism, with high estradiol level observed in 8/190 (4.2%). The prevalence of new glycemic alterations was 17.3% (56/323) [specifically, 32/56 (57.1%) DM, and 24/56 (42.9%) prediabetes]. A thyroid dysfunction was observed in 40/323 subjects (12.3%) and hyperprolactinemia in 37/323 (11.5%). Patients with new diagnosis of DM showed more severe form of ED compared to the total group {difficulty in the achievement of erection: 46/56 [82.2%, vs 265/1332 (19.9%), p < 0.05]; absence of spontaneous erection 23/56 [41.1%, vs 321/1332 (24.1%), p < 0.05]}. CONCLUSION: ED is an early marker of endocrine/glycemic disorder, and a previously unknown dysfunction was found in more than a quarter of patients. A newly diagnosed DM is associated with ED severity, especially in elderly man and in presence of hypertension. |
format | Online Article Text |
id | pubmed-9270283 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-92702832022-07-10 Erectile dysfunction as a marker of endocrine and glycemic disorders Mazzilli, R. Zamponi, V. Olana, S. Mikovic, N. Cimadomo, D. Defeudis, G. Faggiano, A. J Endocrinol Invest Original Article PURPOSE: The aim of this study was to evaluate in a population of patients with erectile dysfunction (ED): (a) the prevalence of a previously unknown endocrine/glycemic disorders; (b) the correlation between ED severity and endocrine/glycemic disorders. METHODS: 1332 patients referred for ED from 2013 to 2020 were included. The ED diagnosis was made using the International-Erectile-Function-Index-5 questionnaire. ED severity was considered according to presence/absence of spontaneous erections, maintenance/achievement deficiency. All patients were subjected to search for sociodemographic and clinical characteristics: age, ethnicity, marital status, previous use of PDE5i, previous prostatectomy, diabetes mellitus (DM), prediabetes, endocrine dysfunctions. RESULTS: The mean ± SD age was 54.3 ± 13.7 years. The 19.1% (255/1332) of patients were already in treatment for prediabetes/diabetes or endocrine dysfunctions. Among the remaining 1077, the prevalence of previously unknown endocrine and glycemic disorders was 30% (323/1077). Among them, 190/323 subjects (58.8%) were affected by hypogonadism, with high estradiol level observed in 8/190 (4.2%). The prevalence of new glycemic alterations was 17.3% (56/323) [specifically, 32/56 (57.1%) DM, and 24/56 (42.9%) prediabetes]. A thyroid dysfunction was observed in 40/323 subjects (12.3%) and hyperprolactinemia in 37/323 (11.5%). Patients with new diagnosis of DM showed more severe form of ED compared to the total group {difficulty in the achievement of erection: 46/56 [82.2%, vs 265/1332 (19.9%), p < 0.05]; absence of spontaneous erection 23/56 [41.1%, vs 321/1332 (24.1%), p < 0.05]}. CONCLUSION: ED is an early marker of endocrine/glycemic disorder, and a previously unknown dysfunction was found in more than a quarter of patients. A newly diagnosed DM is associated with ED severity, especially in elderly man and in presence of hypertension. Springer International Publishing 2022-04-02 2022 /pmc/articles/PMC9270283/ /pubmed/35366160 http://dx.doi.org/10.1007/s40618-022-01788-5 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Mazzilli, R. Zamponi, V. Olana, S. Mikovic, N. Cimadomo, D. Defeudis, G. Faggiano, A. Erectile dysfunction as a marker of endocrine and glycemic disorders |
title | Erectile dysfunction as a marker of endocrine and glycemic disorders |
title_full | Erectile dysfunction as a marker of endocrine and glycemic disorders |
title_fullStr | Erectile dysfunction as a marker of endocrine and glycemic disorders |
title_full_unstemmed | Erectile dysfunction as a marker of endocrine and glycemic disorders |
title_short | Erectile dysfunction as a marker of endocrine and glycemic disorders |
title_sort | erectile dysfunction as a marker of endocrine and glycemic disorders |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270283/ https://www.ncbi.nlm.nih.gov/pubmed/35366160 http://dx.doi.org/10.1007/s40618-022-01788-5 |
work_keys_str_mv | AT mazzillir erectiledysfunctionasamarkerofendocrineandglycemicdisorders AT zamponiv erectiledysfunctionasamarkerofendocrineandglycemicdisorders AT olanas erectiledysfunctionasamarkerofendocrineandglycemicdisorders AT mikovicn erectiledysfunctionasamarkerofendocrineandglycemicdisorders AT cimadomod erectiledysfunctionasamarkerofendocrineandglycemicdisorders AT defeudisg erectiledysfunctionasamarkerofendocrineandglycemicdisorders AT faggianoa erectiledysfunctionasamarkerofendocrineandglycemicdisorders |